A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Clinical trial NCT05947851 · RECRUITING

Trial details

NCT number: NCT05947851
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Chronic Lymphocytic Small-Cell Lymphoma Lymphoma, Small Lymphocytic CLL SLL

Start date: 2023-08-08
Primary completion: 2032-06-01
Enrollment: 735

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.